Enliven Therapeutics, Inc. · NASDAQ:ELVN

Collins Helen Louise sold 5,000 Enliven Therapeutics, Inc. shares (Form 4)

Traded Jul 17, 2026 · Filed Jul 21, 2026

On Jul 17, 2026, Collins Helen Louise (CHIEF MEDICAL OFFICER) sold 5,000 Enliven Therapeutics, Inc. shares at an average US$52.67 for US$263K under a trading plan, leaving 25,000 shares. Filed Jul 21, 2026 (Form 4).

Sold
5,000 shares
Price
US$52.67 average (US$50.05 to US$53.92)
Value
US$263K
Holding after
25,000 shares
Trading plan
Yes (Made under a plan set in advance)
Role
CHIEF MEDICAL OFFICER

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jul 17, 2026Common StockOption exercise5,000US$2.4830,000Direct
Jul 17, 2026Common StockSale231US$50.0529,769Direct
Jul 17, 2026Common StockSale459US$51.5529,310Direct
Jul 17, 2026Common StockSale2,063US$52.3927,247Direct
Jul 17, 2026Common StockSale2,184US$53.4225,063Direct
Jul 17, 2026Common StockSale63US$53.9225,000Direct

Source

View original at SEC

Related